HALO Annual Net Income
$281.59 M
+$79.47 M+39.31%
31 December 2023
Summary:
As of January 22, 2025, HALO annual net profit is $281.59 million, with the most recent change of +$79.47 million (+39.31%) on December 31, 2023. During the last 3 years, it has risen by +$152.51 million (+118.15%). HALO annual net income is now -30.08% below its all-time high of $402.71 million, reached on December 31, 2021.HALO Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Quarterly Net Income
$137.01 M
+$43.77 M+46.94%
30 September 2024
Summary:
As of January 22, 2025, HALO quarterly net profit is $137.01 million, with the most recent change of +$43.77 million (+46.94%) on September 30, 2024. Over the past year, it has increased by +$55.17 million (+67.42%). HALO quarterly net income is now -36.74% below its all-time high of $216.59 million, reached on September 30, 2021.HALO Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO TTM Net Income
$392.47 M
+$55.17 M+16.36%
30 September 2024
Summary:
As of January 22, 2025, HALO TTM net profit is $392.47 million, with the most recent change of +$55.17 million (+16.36%) on September 30, 2024. Over the past year, it has increased by +$138.56 million (+54.57%). HALO TTM net income is now -9.76% below its all-time high of $434.92 million, reached on March 31, 2022.HALO TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +39.3% | +67.4% | +54.6% |
| 3 y3 years | +118.2% | +67.4% | +54.6% |
| 5 y5 years | +450.6% | +67.4% | +54.6% |
HALO Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -30.1% | +39.3% | at high | +504.0% | -9.8% | +116.1% |
| 5 y | 5-year | -30.1% | +489.8% | -36.7% | +498.3% | -9.8% | +589.7% |
| alltime | all time | -30.1% | +373.3% | -36.7% | +498.3% | -9.8% | +427.1% |
Halozyme Therapeutics Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $137.01 M(+46.9%) | $392.47 M(+16.4%) |
| June 2024 | - | $93.25 M(+21.4%) | $337.29 M(+5.8%) |
| Mar 2024 | - | $76.82 M(-10.0%) | $318.80 M(+13.2%) |
| Dec 2023 | $281.59 M(+39.3%) | $85.39 M(+4.3%) | $281.59 M(+10.9%) |
| Sept 2023 | - | $81.84 M(+9.5%) | $253.91 M(+8.6%) |
| June 2023 | - | $74.75 M(+88.7%) | $233.71 M(+28.7%) |
| Mar 2023 | - | $39.62 M(-31.3%) | $181.64 M(-10.1%) |
| Dec 2022 | $202.13 M(-49.8%) | $57.70 M(-6.4%) | $202.13 M(-4.3%) |
| Sept 2022 | - | $61.63 M(+171.7%) | $211.20 M(-42.3%) |
| June 2022 | - | $22.68 M(-62.3%) | $366.15 M(-15.8%) |
| Mar 2022 | - | $60.11 M(-10.0%) | $434.92 M(+8.0%) |
| Dec 2021 | $402.71 M(+212.0%) | $66.77 M(-69.2%) | $402.71 M(-1.6%) |
| Sept 2021 | - | $216.59 M(+136.8%) | $409.10 M(+78.9%) |
| June 2021 | - | $91.46 M(+227.9%) | $228.72 M(+40.3%) |
| Mar 2021 | - | $27.89 M(-61.9%) | $163.08 M(+26.3%) |
| Dec 2020 | $129.09 M(-278.7%) | $73.16 M(+102.1%) | $129.09 M(+499.7%) |
| Sept 2020 | - | $36.21 M(+40.2%) | $21.52 M(-154.2%) |
| June 2020 | - | $25.82 M(-523.0%) | -$39.70 M(-50.5%) |
| Mar 2020 | - | -$6.10 M(-82.3%) | -$80.14 M(+10.9%) |
| Dec 2019 | -$72.24 M(-10.1%) | -$34.40 M(+37.5%) | -$72.24 M(+80.7%) |
| Sept 2019 | - | -$25.02 M(+71.1%) | -$39.97 M(-6.6%) |
| June 2019 | - | -$14.62 M(-914.3%) | -$42.80 M(-16.2%) |
| Mar 2019 | - | $1.80 M(-184.5%) | -$51.07 M(-36.4%) |
| Dec 2018 | -$80.33 M(-227.6%) | -$2.13 M(-92.4%) | -$80.33 M(-275.9%) |
| Sept 2018 | - | -$27.85 M(+21.7%) | $45.68 M(-40.1%) |
| June 2018 | - | -$22.89 M(-16.6%) | $76.28 M(+11.5%) |
| Mar 2018 | - | -$27.46 M(-122.2%) | $68.41 M(+8.6%) |
| Dec 2017 | $62.97 M(-161.1%) | $123.88 M(+4406.4%) | $62.97 M(-171.3%) |
| Sept 2017 | - | $2.75 M(-108.9%) | -$88.30 M(-26.4%) |
| June 2017 | - | -$30.76 M(-6.5%) | -$119.99 M(+3.3%) |
| Mar 2017 | - | -$32.90 M(+20.1%) | -$116.10 M(+12.7%) |
| Dec 2016 | -$103.02 M(+219.6%) | -$27.39 M(-5.4%) | -$103.02 M(+44.5%) |
| Sept 2016 | - | -$28.95 M(+7.7%) | -$71.32 M(+6.7%) |
| June 2016 | - | -$26.88 M(+35.6%) | -$66.83 M(+80.9%) |
| Mar 2016 | - | -$19.82 M(-558.9%) | -$36.94 M(+14.6%) |
| Dec 2015 | -$32.23 M(-52.9%) | $4.32 M(-117.7%) | -$32.23 M(-22.9%) |
| Sept 2015 | - | -$24.46 M(-910.2%) | -$41.82 M(+11.1%) |
| June 2015 | - | $3.02 M(-120.0%) | -$37.64 M(-33.9%) |
| Mar 2015 | - | -$15.11 M(+186.5%) | -$56.94 M(-16.7%) |
| Dec 2014 | -$68.38 M(-18.1%) | -$5.27 M(-74.0%) | -$68.38 M(-19.6%) |
| Sept 2014 | - | -$20.28 M(+24.6%) | -$85.09 M(+1.2%) |
| June 2014 | - | -$16.27 M(-38.7%) | -$84.10 M(-7.3%) |
| Mar 2014 | - | -$26.55 M(+20.7%) | -$90.74 M(+8.7%) |
| Dec 2013 | -$83.48 M | -$21.99 M(+14.0%) | -$83.48 M(+26.7%) |
| Sept 2013 | - | -$19.29 M(-15.8%) | -$65.90 M(-1.1%) |
| June 2013 | - | -$22.91 M(+18.8%) | -$66.61 M(+15.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | -$19.29 M(+337.8%) | -$57.72 M(+7.8%) |
| Dec 2012 | -$53.55 M(+170.9%) | -$4.41 M(-78.0%) | -$53.55 M(-20.7%) |
| Sept 2012 | - | -$20.01 M(+42.7%) | -$67.56 M(+59.4%) |
| June 2012 | - | -$14.02 M(-7.3%) | -$42.39 M(+67.9%) |
| Mar 2012 | - | -$15.12 M(-17.9%) | -$25.25 M(+27.7%) |
| Dec 2011 | -$19.77 M(-62.9%) | -$18.42 M(-456.5%) | -$19.77 M(+8.3%) |
| Sept 2011 | - | $5.17 M(+65.7%) | -$18.25 M(-49.1%) |
| June 2011 | - | $3.12 M(-132.3%) | -$35.82 M(-29.9%) |
| Mar 2011 | - | -$9.64 M(-43.0%) | -$51.09 M(-4.0%) |
| Dec 2010 | -$53.24 M(-8.8%) | -$16.89 M(+36.1%) | -$53.24 M(+8.6%) |
| Sept 2010 | - | -$12.41 M(+2.1%) | -$49.01 M(-3.0%) |
| June 2010 | - | -$12.15 M(+3.1%) | -$50.51 M(-8.9%) |
| Mar 2010 | - | -$11.79 M(-6.9%) | -$55.42 M(-5.0%) |
| Dec 2009 | -$58.36 M(+19.9%) | -$12.66 M(-9.0%) | -$58.36 M(-6.7%) |
| Sept 2009 | - | -$13.91 M(-18.5%) | -$62.52 M(+5.1%) |
| June 2009 | - | -$17.06 M(+15.9%) | -$59.48 M(+11.3%) |
| Mar 2009 | - | -$14.73 M(-12.5%) | -$53.43 M(+9.8%) |
| Dec 2008 | -$48.65 M(+103.6%) | -$16.83 M(+54.8%) | -$48.65 M(+20.0%) |
| Sept 2008 | - | -$10.87 M(-1.2%) | -$40.54 M(+10.5%) |
| June 2008 | - | -$11.00 M(+10.5%) | -$36.69 M(+20.3%) |
| Mar 2008 | - | -$9.95 M(+14.3%) | -$30.49 M(+27.6%) |
| Dec 2007 | -$23.90 M(+62.0%) | -$8.71 M(+23.9%) | -$23.90 M(+22.1%) |
| Sept 2007 | - | -$7.03 M(+46.4%) | -$19.57 M(+20.9%) |
| June 2007 | - | -$4.80 M(+43.0%) | -$16.19 M(+10.7%) |
| Mar 2007 | - | -$3.36 M(-23.3%) | -$14.62 M(-0.9%) |
| Dec 2006 | -$14.75 M(+11.1%) | -$4.38 M(+19.9%) | -$14.75 M(+6.2%) |
| Sept 2006 | - | -$3.65 M(+12.9%) | -$13.89 M(-0.4%) |
| June 2006 | - | -$3.23 M(-7.4%) | -$13.94 M(+2.7%) |
| Mar 2006 | - | -$3.49 M(-0.7%) | -$13.57 M(+2.2%) |
| Dec 2005 | -$13.28 M(+46.0%) | -$3.51 M(-5.1%) | -$13.28 M(+8.5%) |
| Sept 2005 | - | -$3.70 M(+29.0%) | -$12.24 M(+3.8%) |
| June 2005 | - | -$2.87 M(-10.2%) | -$11.79 M(+7.2%) |
| Mar 2005 | - | -$3.19 M(+28.8%) | -$11.00 M(+21.0%) |
| Dec 2004 | -$9.09 M(+329.9%) | -$2.48 M(-23.8%) | -$9.09 M(+19.4%) |
| Sept 2004 | - | -$3.25 M(+56.8%) | -$7.61 M(+58.6%) |
| June 2004 | - | -$2.07 M(+61.5%) | -$4.80 M(+53.4%) |
| Mar 2004 | - | -$1.28 M(+28.2%) | -$3.13 M(+47.9%) |
| Dec 2003 | -$2.12 M(+86.4%) | -$1.00 M(+128.1%) | -$2.12 M(-5.1%) |
| Sept 2003 | - | -$439.00 K(+8.9%) | -$2.23 M(+23.7%) |
| June 2003 | - | -$403.00 K(+48.4%) | -$1.80 M(+27.3%) |
| Mar 2003 | - | -$271.50 K(-75.7%) | -$1.42 M(+24.8%) |
| Dec 2002 | -$1.13 M(+2758.4%) | -$1.12 M(+8752.4%) | -$1.13 M(+5779.3%) |
| Sept 2002 | - | -$12.60 K(-21.7%) | -$19.30 K(+188.1%) |
| June 2002 | - | -$16.10 K(-271.3%) | -$6700.00(-171.3%) |
| Mar 2002 | - | $9400.00 | $9400.00 |
| Dec 2001 | -$39.70 K | - | - |
FAQ
- What is Halozyme Therapeutics annual net profit?
- What is the all time high annual net income for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual net income year-on-year change?
- What is Halozyme Therapeutics quarterly net profit?
- What is the all time high quarterly net income for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly net income year-on-year change?
- What is Halozyme Therapeutics TTM net profit?
- What is the all time high TTM net income for Halozyme Therapeutics?
- What is Halozyme Therapeutics TTM net income year-on-year change?
What is Halozyme Therapeutics annual net profit?
The current annual net income of HALO is $281.59 M
What is the all time high annual net income for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual net profit is $402.71 M
What is Halozyme Therapeutics annual net income year-on-year change?
Over the past year, HALO annual net profit has changed by +$79.47 M (+39.31%)
What is Halozyme Therapeutics quarterly net profit?
The current quarterly net income of HALO is $137.01 M
What is the all time high quarterly net income for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly net profit is $216.59 M
What is Halozyme Therapeutics quarterly net income year-on-year change?
Over the past year, HALO quarterly net profit has changed by +$55.17 M (+67.42%)
What is Halozyme Therapeutics TTM net profit?
The current TTM net income of HALO is $392.47 M
What is the all time high TTM net income for Halozyme Therapeutics?
Halozyme Therapeutics all-time high TTM net profit is $434.92 M
What is Halozyme Therapeutics TTM net income year-on-year change?
Over the past year, HALO TTM net profit has changed by +$138.56 M (+54.57%)